Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclophosphamide + Tecemotide
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
The combination of cyclophosphamide and tecemotide is a therapeutic approach in cancer immunotherapy. Cyclophosphamide is administered at a low dose (typically 300 mg/m² to a maximum of 600 mg) as a single intravenous infusion 3 days prior to the first tecemotide treatment. This preconditioning aims to inhibit regulatory T cells (Tregs) and enhance the immune response. Tecemotide is a synthetic lipopeptide antigen designed to induce a cellular immune response against MUC1-expressing cancer cells. In clinical trials, particularly the phase 3 START trial for non-small-cell lung cancer (NSCLC), patients received this combination following chemoradiotherapy. While the overall trial did not show a significant survival benefit across all patients, a subgroup analysis revealed a notable overall survival benefit in patients who had received concurrent chemoradiotherapy before the cyclophosphamide + tecemotide treatment.
- Brand names
- tecemotide
- Other names
- cyclophosphamide + tecemotide
02
Targets
Major histocompatibility complex peptide-binding groove
Beyond the preview
Go deeper on Cyclophosphamide + Tecemotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyclophosphamide + Tecemotide.